| 國家衛生研究院 |
2019-02 |
A multicenter, phase Ib/2 study of varlitinib plus gemcitabine and cisplatin (gem/cis) for treatment of naive, advanced, or metastatic biliary tract cancer (BTC)
|
Oh, DY;Yong, WP;Chen, LT;Kim, JW;Chang, AYC;Park, JH;Hsieh, CY;Shih, HJ;McIntyre, N;Chen, YC;Chang, WL;McHale, M;Lindmark, B |
| 國家衛生研究院 |
2016-12-30 |
Winner's curse correction and variable thresholding improve performance of polygenic risk modeling based on genome-wide association study summary-level data
|
Shi, J;Park, JH;Duan, J;Berndt, ST;Moy, W;Yu, K;Song, L;Wheeler, W;Hua, X;Silverman, D;Garcia-Closas, M;Hsiung, CA;Figueroa, JD;Cortessis, VK;Malats, N;Karagas, MR;Vineis, P;Chang, IS;Lin, D;Zhou, B;Seow, A;Matsuo, K;Hong, YC;Caporaso, NE;Wolpin, B;Jacobs, E;Petersen, GM;Klein, AP;Li, D;Risch, H;Sanders, AR;Hsu, L;Schoen, RE;Brenner, H;Consortium, MGS GWAS;Gecco;Consortium, The GAME-ON/TROC: GWAS;Consortium, PRACTICAL;Consortium, PanScan;Consortium, The GAME-ON/ELLIPSE;Stolzenberg-Solomon, R;Gejman, P;Lan, Q;Rothman, N;Amundadottir, LT;Landi, MT;Levinson, DF;Chanock, SJ;Chatterjee, N |
